An Unprecedented Screening Format for Small Molecule Binding

Affinity selection mass spectrometry (ASMS) is a technique used to discover small molecules that engage a specific target. Unlike most biophysical approaches, ASMS offers benefits such as:

  • Enabling hit identification for targets not amenable to traditional biochemical assays
  • Identifying non-covalent binders according to their mass ID, minimizing false positive results

However, conventional ASMS requires extensive sample preparation processes, and large pools of compounds that can compromise the target, to isolate a complex and identify the binder. This requirement reduces throughput and increases reagent consumption and thereby costs.

SAMDI ASMS offers better, faster solutions for small molecule binder drug discovery through:

  • Rapid data generation capable of screening millions of compounds in days
  • Identifying binders from compound pools to further accelerate drug discovery
  • A flexible platform amenable to identify binders to protein and oligonucleotide targets
  • Purification of up to 1536 samples in seconds using high-density SAMDI biochips
  • Minimal reagent consumption
  • Parallel off-target screening to ensure compound specificity

For RNA targets, the SAMDI ASMS platform screens for small molecule binders to any oligonucleotide and reveals selective binders and rank order hits through dose response analysis.

High-Throughput ASMS

Learn how SAMDI-MS identifies small-molecule binders of the human rhinovirus 3C protease.

Download the Article